Abstract YO17
Case summary
Serous ovarian cancer accounts for 80% of ovarian cancer, most of them being high grade and the expected survival for recurrent disease is less than 12 months. CDK4/6 inhibitor has shown promising benefit in ER-positive metastatic breast cancer. A phase II trial showed that investigating palbociclib in recurrent ovarian cancer has shown tolerable toxicity profile and radiological median PFS of 3.7 months and Gynecologic Cancer InterGroup CA125 criteria median PFS of 4.0 months. Therefore CDK4/6 inhibitors used alone or as combination could be useful in recurrent ovarian cancer. We report a case of recurrent ovarian cancer treated with palbociclib and letrozole.
Madam X was initially diagnosed with stage 3 ovarian cancer in 1994 at 25-years-old. She underwent TAHBSO, infracolic omentectomy followed by adjuvant carboplatin/paclitaxel. She was disease-free for 19 years until 2013 when she presented with pleural effusion which was confirmed to be recurrent papillary serous carcinoma. She received carboplatin/paclitaxel/bevacizumab combination for 8 months and stopped in view that the patient opted for a drug holiday. In 2016, her pleural effusion worsened. BRCA testing showed no BRCA1/2 mutation. She was then treated with carboplatin & pegylated liposomal doxorubicin for 6 cycles.
In April 2017, she presented with left axillary lymphadenopathy. Core biopsy showed high-grade serous carcinoma, positive for ER & PR; negative for HER2, PDL1 and MSI. She was then commenced on letrozole.
In May 2017, her CA15-3 was increasing from 55U/mL to 77U/mL, and letrozole was changed to tamoxifen. However, CA15-3 continued to rise to 113U/mL within a month. Her performance status was ECOG 0. She was then commenced on palbociclib 125mg OD 3 weeks on and 1 week off schedule with letrozole 2.5mg OD since June 2017. She tolerated palbociclib well and did not require any dose adjustments. The adverse events reported were grade 2 leucopenia and grade 2 neutropenia. CA 15-3 remained to respond for 14 months and she is still ongoing treatment.
In this case, palbociclib and letrozole have shown a prolonged PFS of more than 14 months and an excellent toxicity profile. This could present a potential therapeutic role of CDK4/6 inhibition in recurrent ovarian cancers.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract